Clinical Trial Update: A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 study evaluating the safety and efficacy of AG-013,958 for subfoveal choroidal neovascularization due to age-related macular degeneration…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• AG-013,958

Snippet

Sponsor: Pfizer | Conditions: Age-Related Macular Degeneration | Phase 1, Phase 2 | Status: TERMINATED